News

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17.

“The Catalyst works to help industry partners and academic investigators to raise follow-on funding” said Mike Grisham, CEO of Virginia Catalyst. Through this 17th round of funding, Virginia Catalyst has awarded 69 grants totaling over $36 million, resulting in over $54 million in matching funds and over $700 million in follow-on funding to date.

The Virginia Catalyst in now accepting Letters of Intent for Grant Round 18, until March 14th.
For more information visit: https://www.VirginiaCatalyst.org/apply.html

Grant Round 17 project awardees:

Project: Adenosine A2B receptor blockade for the treatment of Clostridium difficile infection (CDI) •Company: Adovate, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000

Project: Anti-bioflim enzyme (ABE) as a novel, non-toxic solution that overcomes antimicrobial resistance to protect human health from farm to fork
• Company: Lytos Technologies, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000

Project: Orthopaedic Surgical Site Infection Prevention via an Antibiotic Releasing Click Hydrogel
•Company: Pascal Medical Corporation (Richmond, VA)
•University collaborators: Virginia Commonwealth University and George Mason University
•Funding amount: $800,000

Project: Investigational New Drug Enabling Studies of STX2310
•Company: S1P Therapeutics Inc. (Blacksburg, VA)
•University collaborators: Virginia Tech and University of Virginia
•Funding amount: $800,000

 

Recent News

09/16/2025

Lilly announces plans to build $5 billion manufacturing facility in Virginia

Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly’s emerging bioconjugate platform and monoclonal antibody portfolio. Earlier

09/09/2025

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s

09/05/2025

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an ultrasound guidance solution for pediatric lumbar punctures (LPs) on its Accuro® 3S platform. Lumbar punctures